European Journal of Clinical Pharmacology

, Volume 65, Issue 3, pp 309–314 | Cite as

Persistence of antimuscarinic drug use

Pharmacoepidemiology and Prescription

Abstract

Purpose

Evidence suggests antimuscarinic drugs for the overactive-bladder syndrome only confer modest improvements in quality of life. We wanted to describe the persistence of therapy, including an extended analysis beyond the 1-year follow-up employed in other studies.

Methods

All prescriptions for drugs in ATC category G04BD were retrieved for the period 1999–2006 from a regional database with complete capture of all reimbursed prescriptions. Kaplan-Meyer curves were generated for duration of treatment for each substance and analyzed for determinants of termination.

Results

With the exception of trospium chloride, all drugs had continuation rates of less than 50% at 6 months, less than 25% at 1 year, and less than 10% at 2 years and longer. Trospium chloride, however, exhibited continuation rates of 46% at 6 months, 36% at 1 year, 22% at 2 years, and 16% at 3 years.

Conclusions

In a setting of socialized medicine, we found higher continuation rates than previously published. Interestingly, we found that one of the older drugs on the market, trospium chloride, had a strikingly longer retention rate than other drugs.

Keywords

Adherence Antimuscarinic drugs Overactive-bladder syndrome Persistence Pharmacoepidemiology Pharmacological therapy 

References

  1. 1.
    Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A (2002) The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178PubMedCrossRefGoogle Scholar
  2. 2.
    Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760–766 (Erratum in: BJU Int 2001; 88:807)PubMedCrossRefGoogle Scholar
  3. 3.
    Finney SM, Andersson KE, Gillespie JI, Stewart LH (2006) Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions. BJU Int 98:503–507PubMedCrossRefGoogle Scholar
  4. 4.
    Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, Kay G, Laties A, Nathanson NM, Pasricha PJ, Wein AJ (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148:565–578PubMedCrossRefGoogle Scholar
  5. 5.
    Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J (2006) Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 4:CD003781PubMedGoogle Scholar
  6. 6.
    Halaska M, Ralph G, Wiedemann A, Primus G, Ballering-Bruhl B, Hofner K, Jonas U (2003) Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 20:392–399PubMedGoogle Scholar
  7. 7.
    Haab F, Cardozo L, Chapple C, Ridder AM (2005) Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 47:376–384PubMedCrossRefGoogle Scholar
  8. 8.
    Kreder K, Mayne C, Jonas U (2002) Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 41:588–595PubMedCrossRefGoogle Scholar
  9. 9.
    Haab F, Corcos J, Siami P, Glavind K, Dwyer P, Steel M, Kawakami F, Lheritier K, Steers WD (2006) Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int 98:1025–1032PubMedCrossRefGoogle Scholar
  10. 10.
    Yu YF, Nichol MB, Yu AP, Ahn J (2005) Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health 8:495–505PubMedCrossRefGoogle Scholar
  11. 11.
    Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z (2005) Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Managed Care 11:S121–S129Google Scholar
  12. 12.
    Chui MA (2004) Patient persistence with medication for overactive bladder. Value Health 7:366Google Scholar
  13. 13.
    Zhou Z, Barr C, Torigoe Y, Williamson T (2001) Persistence of therapy with drugs for overactive bladder. Value Health 4:161Google Scholar
  14. 14.
    Kelleher CJ, Cardozo LD, Khullar V, Salvatore S (1997) A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 104:988–993PubMedGoogle Scholar
  15. 15.
    Saks EK, Northington G, Gopal M, Arya L (2006) Adherence to anti-cholinergic medications in women with urge incontinence. Int Urogyn J 7:5398Google Scholar
  16. 16.
    Gaist D, Sørensen HT, Hallas J (1997) The Danish prescription registers. Dan Med Bull 44:445–448PubMedGoogle Scholar
  17. 17.
    Hallas J, Stovring H (2006) Templates for analysis of individual-level prescription data. Basic Clin Pharmacol Toxicol 98:260–265PubMedCrossRefGoogle Scholar
  18. 18.
    Hallas J, Gaist D, Bjerrum L (1997) The waiting-time distribution for prescription drugs. Epidemiology 8:666–670PubMedCrossRefGoogle Scholar
  19. 19.
    Cox DR (1972) Regression models and life tables. J R Stat Soc B 34:187–220Google Scholar
  20. 20.
    Bourgault C, Sénécal M, Brisson M, Marentette MA, Grégoire J-P (2005) Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Human Hypertens 19:607–613CrossRefGoogle Scholar
  21. 21.
    Pesce F, Rubilotta E, D’Amico A, Siracusano S, Righetti R, Celia A, Tiberio A, Artibani W (2003) Long-term anticholinergic therapy: duration and causes of discontinuation. Abstract 304 [poster]. International Continence Society 2003, 25–27 August 2003, Paris, FranceGoogle Scholar
  22. 22.
    Brubaker L, Nichol M, Fanning K, Becker R, Jumadilova Z, Benner J (2006) Patient-reported reasons for discontinuing overactive bladder (OAB) medications. Neurourol Urodyn 25:614Google Scholar
  23. 23.
    Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J (2005) A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48:464–470PubMedGoogle Scholar
  24. 24.
    Boccuzzi SJ, Le TK, Wogen J, Williamson T (2002) Utilization patterns associated with tolterodine immediate release versus oxybutinin in the management of urinary incontinence (UI). Value Health 5:274Google Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyGlostrup HospitalGlostrupDenmark
  2. 2.Research Unit of Clinical PharmacologyUniversity of Southern DenmarkOdenseDenmark

Personalised recommendations